Clinical Trial Update: Camrelizumab /Apatinib for Recurrent Platinum-resistant Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update for camrelizumab in combination with apatinib in recurrent platinum-resistant ovarian cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Apatinib (apatinib)
• Camrelizumab (camrelizumab)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Recurrent Platinum-resistant Ovarian Cancer | Phase 2 | Status: UNKNOWN